Testing for aldosterone levels may hold the key to treatment-resistant hypertension and many other cardiac conditions, but ...

Higher serum aldosterone levels among patients with chronic kidney disease (CKD) are independently associated with an increased risk for CKD progression and end-stage kidney disease (ESKD) regardless ...

A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...

Currently, patients with HFpEF have high risk of morbidity and mortality, but there is no effective measure for evaluating the prognosis. Studies have found that a variety of ways can lead to the ...

The coronavirus disease 2019 (COVID-19) pandemic caused millions of deaths throughout the world, which has provoked intense research into the pathogenetic mechanism behind this disease. A new study ...

Hyperaldosteronism is when one or both adrenal glands release too much of the hormone aldosterone. High blood pressure can result, which could lead to atrial fibrillation, heart attack, or stroke.

Currently, patients with HFpEF have high risk of morbidity and mortality, but there is no effective measure for evaluating the prognosis. Studies have found that a variety of ways can lead to the ...

Please provide your email address to receive an email when new articles are posted on . Dysregulated aldosterone production, sometimes driven by obesity, can cause hypertension. Targeted therapies ...

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat safely lowered 24-hour systolic BP compared with placebo in a phase 2 trial. A ...

Mineralys Therapeutics, Inc. has announced the publication of detailed results from its pivotal Phase 2 Advance-HTN trial in the New England Journal of Medicine. The study assessed lorundrostat, an ...